Shire To Test Convenience Versus Familiarity In HAE Space With Approval Of Firazyr
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Firazyr for acute treatment of HAE attacks, with a label that allows for self-administration.
You may also be interested in...
Pharming/Santarus’ Recombinant HAE Drug Ruconest Goes Back To FDA
A BLA has been re-submitted to FDA for Ruconest, which is differentiated from other C1 esterase inhibitors by its recombinant structure. But as the fifth drug for the rare hereditary angioedema condition in the U.S. market, commercial expectations are low.
Pharming/Santarus’ Recombinant HAE Drug Ruconest Goes Back To FDA
A BLA has been re-submitted to FDA for Ruconest, which is differentiated from other C1 esterase inhibitors by its recombinant structure. But as the fifth drug for the rare hereditary angioedema condition in the U.S. market, commercial expectations are low.
Is Europe's HAE Market Big Enough To Sustain All The Competitors?
As more companies of all sizes embrace rare diseases – lured in part by supposed lower regulatory and reimbursement hurdles – some niche markets are beginning to look rather busy.